In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...
Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its ...
The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...
2d
It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Emirates Health Services EHS takes centre stage at Arab Health 2025 medical expo showcasing a series of groundbreaking ...
DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...
Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...
Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...
Beta Bionics, Inc. (BBNX) is planning to raise $112 million in an initial public offering on Thursday, January 30th, IPO Scoop reports. The company will be issuing 7,500,000 shares at $14.00-$16.00 ...
Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback